| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8430dfed10baf5168628141d8c8d4f09 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-718
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-413
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-413
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate |
2005-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d32661fc57748df4dcbb8c747c3c1579 |
| publicationDate |
2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7772220-B2 |
| titleOfInvention |
Methods and compositions for reducing toxicity of a pharmaceutical compound |
| abstract |
The present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having one or more toxic effects. In some embodiments, solutions of the disclosure are administered to a mammal in conjunction with a pharmaceutical compound associated with a peripherial neurotoxicity (e.g., cisplatin and/or suramin) to reduce or eliminate the neuropathic effect(s). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9511045-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102178685-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102178685-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013064775-A1 |
| priorityDate |
2004-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |